Stephane Hominal
Pringy, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Fusion isoform multiplicity and impact on treatment outcomes in ALK-rearranged non-small cell lung cancer with next-generation tyrosine kinase inhibitors.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 11, 2026
Real-life management and outcomes of octogenarians with non-small-cell lung cancer: A 10-year evolution.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 22, 2026
First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing ≥ 50% PD-L1 (ESCKEYP GFPC 05-2018).
Journal: Clinical lung cancer
Published: November 17, 2024
LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: July 30, 2024
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
Journal: The Lancet. Respiratory medicine
Published: May 16, 2024
Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 30, 2024
Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 15, 2024
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 07, 2023
Performance of an eHealth (NOMHAD) System Comprising Telemonitoring, Telenotification, and Telecoaching for Patients With Multimorbidity: Proof-of-Concept Study.
Journal: JMIR formative research
Published: August 09, 2021
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 31, 2020
Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study.
Journal: Respiratory medicine and research
Published: April 01, 2020
One-year survival improvement in lung cancer in France. Results of the prospective real life studies KBP-2000-CPHG and KBP-2010-CPHG
Journal: Revue de pneumologie clinique
Published: February 21, 2016
Last Updated: 09/26/2026